Nektar Therapeutics
NKTRNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for NKTR. That does not mean none is planned.
Get an email about NKTR's next catalysts
Track Nektar Therapeutics (NKTR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
NKTR Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-2.16 | FQ end Sep/2026 | Call: amc
Market Overview
Stock performance and key metrics
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
WebsiteNKTR-102
Tumor
NKTR-181 BID tablets
Low Back Pain
Rezpegaldesleukin
Moderate to Severe Atopic Dermatitis
Eribulin
Metastasis
NKTR-181
Osteoarthritis of the Knee
NKTR-255
Head and Neck Squamous Cell Carcinoma
Pegylated Irinotecan
Stage IV Non-small Cell Lung Cancer (NSCLC)
aerosolized vancomycin or gentamicin
Ventilator Associated Pneumonia
Amikacin inhalation solution (BAY41-6551)
Pneumonia
Etirinotecan pegol
Anaplastic Astrocytomas
Dronabinol MDI
Migraine With Aura
JB100
Locally Advanced or Metastatic Urothelial Carcinoma
NKTR-214
Unspecified Adult Solid Tumor, Protocol Specific
NKTR-102 q21d
Tumor
Bempegaldesleukin
Urinary Bladder Neoplasm
LY3471851
Systemic Lupus Erythematosus
NKTR-102 q14d
Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NKTR-102 | Phase 3 | Tumor | - | - |
NKTR-181 BID tablets | Phase 3 | Low Back Pain | - | - |
Rezpegaldesleukin | Phase 3 | Moderate to Severe Atopic Dermatitis | - | - |
Eribulin | Phase 3 | Metastasis | - | - |
NKTR-181 | Phase 2 | Osteoarthritis of the Knee | - | - |
NKTR-255 | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Pegylated Irinotecan | Phase 2 | Stage IV Non-small Cell Lung Cancer (NSCLC) | - | - |
aerosolized vancomycin or gentamicin | Phase 2 | Ventilator Associated Pneumonia | - | - |
Amikacin inhalation solution (BAY41-6551) | Phase 2 | Pneumonia | - | - |
Etirinotecan pegol | Phase 2 | Anaplastic Astrocytomas | - | - |
Dronabinol MDI | Phase 2 | Migraine With Aura | - | - |
JB100 | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma | - | - |
NKTR-214 | Phase 2 | Unspecified Adult Solid Tumor, Protocol Specific | - | - |
NKTR-102 q21d | Phase 2 | Tumor | - | - |
Bempegaldesleukin | Phase 2 | Urinary Bladder Neoplasm | - | - |
LY3471851 | Phase 2 | Systemic Lupus Erythematosus | - | - |
NKTR-102 q14d | Phase 2 | Tumor | - | - |
Unspecified Adult Solid Tumor, Protocol Specific
1 drug in this indication
Urinary Bladder Neoplasm
1 drug in this indication
Moderate to Severe Atopic Dermatitis
1 drug in this indication
Alopecia Areata and Atopic Dermatitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Nektar Therapeutics's drug pipeline?→
CatalystAlert tracks 17 drug candidates in Nektar Therapeutics's (NKTR) pipeline across Phase 3, Phase 2. Its lead program is Eribulin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nektar Therapeutics's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Nektar Therapeutics (NKTR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track NKTR biotech catalysts?→
Add NKTR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nektar Therapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.